CU6 Shares Clarity Pharmaceuticals Ltd
ASX · ASXLast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Late-stage radiopharmaceutical trials and FDA ambitions create significant medium-term commercial optionality.
Signal breakdown
- ▸Two Phase III trials progressing toward potential FDA approval.
- ▾Below 50-day MA (-25.84%)
- ▸Volume 1.61× average — accumulation
- ▾Near 52-week low (1.7% of range)
Is CU6 a buy right now?
Trend: CU6 is trading below the 50-day average (-25.71%), RSI 59 — neutral momentum, with a 3-month return of -24.64%.
Valuation & quality: Clarity Pharmaceuticals Ltd trades on forward P/E -5.9, price-to-book 3.16; fundamentals show net margin 0.0%, return on equity -77.5%, revenue growth -1.1% year on year.
Analyst consensus: 4 analysts have a mean 12-month price target of A$7.20 (+356.8% vs the last close; range A$5.60 – A$8.40), consensus rating “none”.
Our screen: BUY (score 2) — Late-stage radiopharmaceutical trials and FDA ambitions create significant medium-term commercial optionality.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.00% | -14.80% | -12.00% | -14.10% | +10.70% | -3.80% | -7.90% | -24.80% |
Fundamentals
Analyst price target
Technical signals
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States.
Sector: Healthcare · Industry: Biotechnology · Australia · 100 employees · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.